HUMACYTE INC

NASDAQ: HUMA (Humacyte, Inc.)

Kemas kini terakhir: 4 hari lalu, 7:55AM

1.29

0.03 (2.38%)

Penutupan Terdahulu 1.26
Buka 1.29
Jumlah Dagangan 3,179,325
Purata Dagangan (3B) 5,236,801
Modal Pasaran 241,580,000
Harga / Pendapatan (P/E Ke hadapan) 35.84
Harga / Jualan (P/S) 112.08
Harga / Buku (P/B) 70.17
Julat 52 Minggu
1.09 (-15%) — 6.77 (424%)
Tarikh Pendapatan 12 Nov 2025
Margin Operasi (TTM) -4,484.33%
EPS Cair (TTM) -0.690
Jumlah Hutang/Ekuiti (D/E MRQ) 228.93%
Nisbah Semasa (MRQ) 3.68
Aliran Tunai Operasi (OCF TTM) -99.38 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -67.40 M
Pulangan Atas Aset (ROA TTM) -42.82%
Pulangan Atas Ekuiti (ROE TTM) -249.75%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Humacyte, Inc. Menaik Menurun

AISkor Stockmoo

1.5
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.0
Purata 1.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
HUMA 242 M - - 70.17
MESO 2 B - - 3.70
TSHA 1 B - - 5.08
QURE 1 B - - 5.81
SANA 1 B - - 6.10
NKTR 1 B - - 13.66

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 20.16%
% Dimiliki oleh Institusi 40.20%
Julat 52 Minggu
1.09 (-15%) — 6.77 (424%)
Julat Harga Sasaran
6.00 (365%) — 25.00 (1837%)
Tinggi 25.00 (D. Boral Capital, 1,837.98%) Beli
Median 11.00 (752.71%)
Rendah 6.00 (BTIG, 365.12%) Beli
Purata 14.00 (985.27%)
Jumlah 3 Beli
Harga Purata @ Panggilan 1.18
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BTIG 21 Nov 2025 6.00 (365.12%) Beli 1.22
13 Oct 2025 6.00 (365.12%) Beli 1.76
D. Boral Capital 20 Nov 2025 25.00 (1,837.98%) Beli 1.12
13 Nov 2025 25.00 (1,837.98%) Beli 1.19
Benchmark 13 Nov 2025 11.00 (752.71%) Beli 1.19

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
20 Nov 2025 Pengumuman Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
13 Nov 2025 Pengumuman Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
12 Nov 2025 Pengumuman Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
10 Nov 2025 Pengumuman Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
06 Nov 2025 Pengumuman Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
30 Oct 2025 Pengumuman Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
14 Oct 2025 Pengumuman D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering
07 Oct 2025 Pengumuman Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
06 Oct 2025 Pengumuman Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
29 Sep 2025 Pengumuman Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
18 Sep 2025 Pengumuman Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
15 Sep 2025 Pengumuman Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda